Please use this identifier to cite or link to this item: http://hdl.handle.net/2080/5122
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKirthik, Roshan M-
dc.contributor.authorJaiswal, Sushila-
dc.contributor.authorJaiswal, Awadesh K.-
dc.contributor.authorSrinivasan, M-
dc.date.accessioned2025-03-18T05:09:46Z-
dc.date.available2025-03-18T05:09:46Z-
dc.date.issued2025-02-
dc.identifier.citation7th Annual Conference of the Neuropathology Society of India (NPSICON), AIIMS, New Delhi, 20-22 February 2025en_US
dc.identifier.urihttp://hdl.handle.net/2080/5122-
dc.descriptionCopyright belongs to the proceeding publisheren_US
dc.description.abstractGlioblastoma is an aggressive brain tumour with poor prognosis. Recent findings suggest that RNA modifiers could be a determinant of oncogenicity and resistance phenotype. N6-methyladenosine RNA methylation is a dynamic modification enriched in the 3’UTR and determines the RNA fate. Studies have suggested that downregulating writers and erasers of m6A modifiers decreases oncogenicity. The present study will highlight m6A modifiers role in glioma. A total of 29 samples included in the study collected from SGPGIMS, Lucknow, UP and all were adult type diffusive glioma (Glioblastoma (n=12), Astrocytoma-IDH mutant (n=14) and Oligodendroglioma IDH mutant & 1p19q co-deleted (n=3)). According to WHO 2021 CNS tumor classification samples were grouped. We performed the qRT-PCR and western blotting for quantifying the different class of m6A RNA modifiers. The qRT PCR analysis showed a statistically significant differential expression of RBM15 (m6A writer) between Astrocytoma-IDH mutant, grade 4 and Oligodendroglioma-IDH mutant & 1p-19q co-deleted, grade 2 with a mean difference of ±3.55; ALKBH5 (m6A eraser) between Astrocytoma-IDH mutant, grade 3 and Oligodendroglioma-IDH mutant & 1p-19q co-deleted, grade 2 with a mean difference of ±28.9; and YTHDF3 (m6A reader) between Astrocytoma-IDH mutant, grade 4 and Astrocytoma-IDH mutant, grade 3 with a mean difference of ±0.51, and also between Glioblastoma and Astrocytoma-IDH mutant, grade 4 with a mean difference of ±0.42. The previous studies suggested that these RNA modifiers promote oncogenic properties of glioblastoma and other cancer. Further studies will be carried out to rule out the oncogenic properties of these RNA modifiers in glioma.en_US
dc.subjectCanceren_US
dc.subjectEpitranscriptomeen_US
dc.subjectGliomaen_US
dc.subjectN6-Methyladenosineen_US
dc.subjectRNA modificationen_US
dc.titleDifferential Expression of m6A RNA Modifiers in Gliomasen_US
dc.typePresentationen_US
Appears in Collections:Conference Papers

Files in This Item:
File Description SizeFormat 
2025_NPSICON_KRoshanM_Differential.pdfPresentation1.03 MBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.